Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis

Inclusion Criteria: * Patients who sign the Deed of Consent (IC) in two ways, by his own free will, agreeing with all study procedures; * Patients older than 18 years, any ethnicity, class or social group, regardless of sex; * Patients with pictures of dermatoses acute, subacute or chronic, of inflammatory origin and / or allergic, to which it is recommended the use of drugs under investigation topically, such as: * atopic dermatitis, * prurigo, * primary contact dermatitis or allergic * urticaria, * pharmacodermic, * allergic vasculitis, * dyshidrosis, Exclusion Criteria: * Patients being treated with antibiotics; * Participation in clinical trials in the 12 months preceding the survey; * Current treatment with immunosuppressants (eg, cyclosporine or methotrexate); * Current treatment with phototherapy (UVA, UVB, PUVA and lasers); * Use of systemic corticosteroids at inclusion visit or within 15 days prior to inclusion; * Topical treatments at the site of acne in the 15 days preceding the visit of inclusion; * Presence of any skin condition in areas affected by acne that hamper the evolutionary analysis of the lesion; * Presence of secondary infections at the site of treatment, diagnosed clinically; * Presence of other eczematous picture, such as nummular eczema, neurodermatitis, seborrheic dermatitis, psoriasis, scabies, and Buckley's syndrome Wiskott-Aldrich; * Pregnant or lactating women; * Chronic alcoholism; * Patients with a history of hypersensitivity to any component of the formulas of the products under investigation; * Any finding of clinical observation (clinical history or physical examination) that is interpreted by the physician investigator as a risk to the patient's participation in the study; * Allergic Dermatosis of moderate or severe that, according to the investigator, is not justified topical.